01:41 PM EDT, 07/22/2025 (MT Newswires) -- Vertex Pharmaceuticals ( VRTX ) said Tuesday its cystic fibrosis treatment Alyftrek has received marketing authorization from Health Canada.

The once-daily triple combination therapy is approved for patients aged 6 years and older with at least one F508del mutation or another responsive cystic fibrosis transmembrane conductance regulator, or CFTR, mutation.

About 3,800 people in Canada are now eligible for Alyftrek, including up to 60 who were not previously eligible for a CFTR modulator, according to the company.

Shares of Vertex Pharmaceuticals ( VRTX ) were up over 2% in recent trading.

Price: 468.83, Change: +10.34, Percent Change: +2.25